ITI-1020

ITI-1020 is an investigational small molecule drug being developed as a cancer immunotherapy. It is a phosphodiesterase type 1 (PDE1) inhibitor, designed to modulate immune responses in oncology indications. The drug is currently in Phase 1 clinical trials, where it is being evaluated for safety, tolerability, and pharmacokinetics in healthy volunteers. ITI-1020 represents the second PDE1 inhibitor from Intra-Cellular Therapies' pipeline and aims to leverage immunostimulatory mechanisms for potential anti-tumor effects[2][4][5][6][7][8][9][10]. There are also references to an autologous dendritic cell vaccine candidate named ITI 1020 developed by Immunomic Therapeutics for glioblastoma; however, the primary ongoing development as of 2025 appears to be as a small molecule PDE1 inhibitor by Intra-Cellular Therapies[1].